Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …

Background To undertake an economic evaluation of rivaroxaban relative to the standard of
care for stroke prevention in patients with non-valvular atrial fibrillation (AF) in Greece …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

Background Warfarin, an inexpensive drug that has been available for over half a century,
has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial …

Background: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF)
imposes a substantial economic burden on the UK healthcare system. Objectives: An …

Objective The aim of this study was to assess the cost effectiveness of the novel fixed-dose
anticoagulant rivaroxaban compared with the current standard of care, warfarin, for the …

Objectives To evaluate the cost-effectiveness of the once daily oral anticoagulant
rivaroxaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation …

Abstract Introduction and Aims To project the long-term cost-effectiveness of treating non-
valvular atrial fibrillation (AF) patients for stroke prevention with rivaroxaban compared to …

Background and Purpose—We compared the 1-year safety and effectiveness of rivaroxaban
15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with …

Objectives Management with vitamin K antagonists (VKAs) has been an effective and cost-
effective strategy for stroke prevention in atrial fibrillation (AF) but is associated with …